HD004 / Huadao (Shanghai) Biopharmaceutical - LARVOL DELTA

Huadao Biotech achieves breakthrough with first solid tumor CAR-T therapy [Google translation] (SHINE) - "Huadao (Shanghai) Biopharmaceutical Co Ltd has announced a major advancement in immunotherapy with the approval of its first CAR-T cell therapy for solid tumors. The therapy, HD004, is the world's first cellular treatment targeting CLDN18.2-positive advanced solid tumor malignant ascites, marking a significant step towards making CAR-T therapies more accessible in China."

New trial • Solid Tumor